NASDAQ:FOMX - Foamix Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$5.12 +0.07 (+1.39 %)
(As of 06/24/2018 03:06 AM ET)
Previous Close$5.12
Today's Range$5.03 - $5.17
52-Week Range$4.33 - $7.45
Volume41,451 shs
Average Volume75,633 shs
Market Capitalization$204.54 million
P/E Ratio-2.91
Dividend YieldN/A
Beta1.9
Foamix Pharmaceuticals logoFoamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations primarily for the treatment of moderate-to-severe acne, moderate-to-severe papulo-pustular rosacea, and other skin conditions in the United States and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline, which has completed a double-blind and dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus. The company is also developing FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea; and FDX104 that has completed Phase II clinical trial for the treatment of chemotherapy-induced rash. Foamix Pharmaceuticals Ltd. has development and license agreements with Bayer HealthCare AG; Mylan N.V.; and Actavis Laboratories. The company was founded in 2003 and is headquartered in Rehovot, Israel.

Receive FOMX News and Ratings via Email

Sign-up to receive the latest news and ratings for FOMX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:FOMX
CUSIPN/A
Phone972-8931-6233

Debt

Debt-to-Equity RatioN/A
Current Ratio4.54
Quick Ratio4.54

Price-To-Earnings

Trailing P/E Ratio-2.91
Forward P/E Ratio-2.91
P/E GrowthN/A

Sales & Book Value

Annual Sales$3.67 million
Price / Sales56.50
Cash FlowN/A
Price / CashN/A
Book Value$1.83 per share
Price / Book2.80

Profitability

EPS (Most Recent Fiscal Year)($1.76)
Net Income$-65,710,000.00
Net Margins-2,119.19%
Return on Equity-103.64%
Return on Assets-90.44%

Miscellaneous

Employees75
Outstanding Shares40,500,000

The Truth About Cryptocurrencies

Foamix Pharmaceuticals (NASDAQ:FOMX) Frequently Asked Questions

What is Foamix Pharmaceuticals' stock symbol?

Foamix Pharmaceuticals trades on the NASDAQ under the ticker symbol "FOMX."

How were Foamix Pharmaceuticals' earnings last quarter?

Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) announced its quarterly earnings results on Wednesday, May, 9th. The specialty pharmaceutical company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by $0.24. The specialty pharmaceutical company had revenue of $0.91 million for the quarter, compared to analyst estimates of $1.11 million. Foamix Pharmaceuticals had a negative net margin of 2,119.19% and a negative return on equity of 103.64%. View Foamix Pharmaceuticals' Earnings History.

When is Foamix Pharmaceuticals' next earnings date?

Foamix Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for Foamix Pharmaceuticals.

What price target have analysts set for FOMX?

3 brokerages have issued twelve-month price objectives for Foamix Pharmaceuticals' stock. Their forecasts range from $8.00 to $12.00. On average, they expect Foamix Pharmaceuticals' share price to reach $9.6667 in the next twelve months. View Analyst Ratings for Foamix Pharmaceuticals.

Who are some of Foamix Pharmaceuticals' key competitors?

Who are Foamix Pharmaceuticals' key executives?

Foamix Pharmaceuticals' management team includes the folowing people:
  • Mr. David T. Domzalski, CEO, Director & Pres of Foamix Pharmaceuticals Inc. (Age 51)
  • Mr. Meir Eini, Co-Founder & Innovation Advisor (Age 63)
  • Mr. Ilan Hadar MBA, CFO & Country Mang. (Age 49)
  • Mr. Yohan Hazot, Chief Technology Officer (Age 35)
  • Ms. Mutya Harsch, Gen. Counsel & Sr. VP of Legal Affairs

Has Foamix Pharmaceuticals been receiving favorable news coverage?

Media stories about FOMX stock have trended somewhat positive recently, Accern reports. Accern rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Foamix Pharmaceuticals earned a news impact score of 0.08 on Accern's scale. They also assigned news coverage about the specialty pharmaceutical company an impact score of 47.97 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Who are Foamix Pharmaceuticals' major shareholders?

Foamix Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Opaleye Management Inc. (2.35%), Millennium Management LLC (1.88%), BlackRock Inc. (1.24%), Handelsbanken Fonder AB (0.90%), Handelsbanken Fonder AB (0.90%) and DAFNA Capital Management LLC (0.83%). Company insiders that own Foamix Pharmaceuticals stock include David Domzalski, Meir Eini, Russell P Elliott and Stanley Hirsch. View Institutional Ownership Trends for Foamix Pharmaceuticals.

Which major investors are selling Foamix Pharmaceuticals stock?

FOMX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., DAFNA Capital Management LLC, Wells Fargo & Company MN and Opaleye Management Inc.. Company insiders that have sold Foamix Pharmaceuticals company stock in the last year include David Domzalski, Meir Eini, Russell P Elliott and Stanley Hirsch. View Insider Buying and Selling for Foamix Pharmaceuticals.

Which major investors are buying Foamix Pharmaceuticals stock?

FOMX stock was acquired by a variety of institutional investors in the last quarter, including Eversept Partners LLC, Handelsbanken Fonder AB, Handelsbanken Fonder AB, Sofinnova Ventures Inc, A.R.T. Advisors LLC and Millennium Management LLC. View Insider Buying and Selling for Foamix Pharmaceuticals.

How do I buy shares of Foamix Pharmaceuticals?

Shares of FOMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Foamix Pharmaceuticals' stock price today?

One share of FOMX stock can currently be purchased for approximately $5.12.

How big of a company is Foamix Pharmaceuticals?

Foamix Pharmaceuticals has a market capitalization of $204.54 million and generates $3.67 million in revenue each year. The specialty pharmaceutical company earns $-65,710,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis. Foamix Pharmaceuticals employs 75 workers across the globe.

How can I contact Foamix Pharmaceuticals?

Foamix Pharmaceuticals' mailing address is 2 HOLZMAN ST. WEIZMANN SCIENCE PARK, REHOVOT L3, 76704. The specialty pharmaceutical company can be reached via phone at 972-8931-6233 or via email at [email protected]


MarketBeat Community Rating for Foamix Pharmaceuticals (FOMX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  141 (Vote Outperform)
Underperform Votes:  142 (Vote Underperform)
Total Votes:  283
MarketBeat's community ratings are surveys of what our community members think about Foamix Pharmaceuticals and other stocks. Vote "Outperform" if you believe FOMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FOMX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.